Ophthotech Corporation (NASDAQ:OPHT) – Analysts at Gabelli lifted their FY2017 earnings per share (EPS) estimates for shares of Ophthotech Corporation in a report issued on Friday. Gabelli analyst K. Kedra now anticipates that the biopharmaceutical company will earn $2.90 per share for the year, up from their previous estimate of $2.65.
Several other equities analysts have also weighed in on OPHT. ValuEngine upgraded shares of Ophthotech Corporation from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Stifel Nicolaus restated a “hold” rating and set a $4.00 price objective on shares of Ophthotech Corporation in a research report on Thursday, September 21st. Finally, Zacks Investment Research upgraded shares of Ophthotech Corporation from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective for the company in a research report on Monday. Twelve equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $8.31.
TRADEMARK VIOLATION WARNING: This news story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2017/11/15/ophthotech-corporation-opht-forecasted-to-post-fy2017-earnings-of-2-90-per-share.html.
Ophthotech Corporation (NASDAQ OPHT) opened at $3.10 on Monday. Ophthotech Corporation has a 12-month low of $2.24 and a 12-month high of $40.34. The firm has a market cap of $103.07, a PE ratio of 1.82 and a beta of 1.40.
A number of hedge funds have recently bought and sold shares of OPHT. Creative Planning lifted its stake in Ophthotech Corporation by 4,867.3% during the second quarter. Creative Planning now owns 46,941 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 45,996 shares in the last quarter. Federated Investors Inc. PA lifted its stake in Ophthotech Corporation by 102.3% during the second quarter. Federated Investors Inc. PA now owns 55,461 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 28,040 shares in the last quarter. LMR Partners LLP purchased a new stake in Ophthotech Corporation during the second quarter valued at about $269,000. KCG Holdings Inc. purchased a new stake in Ophthotech Corporation during the first quarter valued at about $354,000. Finally, Schwab Charles Investment Management Inc. lifted its stake in Ophthotech Corporation by 73.2% during the first quarter. Schwab Charles Investment Management Inc. now owns 118,166 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 49,928 shares in the last quarter. 62.30% of the stock is owned by institutional investors.
About Ophthotech Corporation
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech Corporation and related companies with MarketBeat.com's FREE daily email newsletter.